Open AccessGH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults
Author(s) -
D B Allen,
Philippe Backeljauw,
Martin Bidlingmaier,
Beverly M. K. Biller,
Margaret Cristina da Silva Boguszewski,
Pia Burman,
G Butler,
Kazuo Chihara,
Jens Sandahl Christiansen,
Stefano Cianfarani,
Peter Clayton,
David R. Clemmons,
Pinchas Cohen,
Feyza Darendelıler,
Cheri Deal,
David Dunger,
Eva Marie Erfurth,
John S. Fuqua,
Adda Grimberg,
Morey W. Haymond,
Claire Higham,
Ken K. Y. Ho,
Andrew R. Hoffman,
Anita Hokken-Koelega,
Gudmundur Johannsson,
Anders Juul,
John J. Kopchick,
Phillip Lee,
Michaël Pollak,
Sally Radovick,
Leslie L. Robison,
Ron G. Rosenfeld,
Richard Ross,
Lars Sävendahl,
Paul Saenger,
Henrik Toft Sørensen,
Kirstine Stochholm,
Christian J. Strasburger,
Anthony J. Swerdlow,
MO Thorner
Publication year - 2015
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-15-0873
Subject(s) - recombinant dna , endocrinology , medicine , critical appraisal , human growth hormone , position (finance) , growth hormone , biology , alternative medicine , hormone , pathology , genetics , finance , economics , gene
Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom